News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
131,411 Results
Type
Article (7609)
Company Profile (57)
Press Release (123742)
Multimedia
Podcasts (22)
Webinars (5)
Section
Business (38468)
Career Advice (89)
Deals (5996)
Drug Delivery (10)
Drug Development (23813)
Employer Resources (12)
FDA (3063)
Job Trends (3592)
News (69222)
Policy (4617)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Standard (1)
Academia (328)
Accelerated approval (12)
Adcomms (13)
Allergies (3)
Alliances (11291)
ALS (21)
Alzheimer's disease (162)
Antibody-drug conjugate (ADC) (255)
Approvals (3223)
Artificial intelligence (174)
Autoimmune disease (54)
Automation (5)
Bankruptcy (55)
Best Places to Work (3303)
BIOSECURE Act (1)
Biosimilars (91)
Biotechnology (50)
Bladder cancer (126)
Brain cancer (48)
Breast cancer (490)
Cancer (3534)
Cardiovascular disease (36)
Career advice (82)
Career pathing (5)
CAR-T (127)
CDC (4)
Cell therapy (267)
Cervical cancer (18)
Clinical research (21246)
Collaboration (684)
Company closure (2)
Compensation (216)
Complete response letters (10)
COVID-19 (352)
CRISPR (27)
C-suite (294)
Cystic fibrosis (8)
Data (2266)
Decentralized trials (1)
Denatured (4)
Depression (11)
Diabetes (38)
Diagnostics (1408)
Digital health (8)
Diversity (2)
Diversity, equity & inclusion (5)
Drug discovery (98)
Drug pricing (25)
Drug shortages (1)
Duchenne muscular dystrophy (27)
Earnings (13979)
Editorial (12)
Employer branding (2)
Employer resources (13)
Events (24901)
Executive appointments (316)
FDA (3912)
Fibrodysplasia Ossificans Progressiva (3)
Frontotemporal dementia (2)
Funding (329)
Gene editing (45)
Generative AI (17)
Gene therapy (91)
GLP-1 (127)
Government (489)
Guidances (87)
Healthcare (4070)
HIV (8)
Huntington's disease (3)
IgA nephropathy (17)
Immunology and inflammation (70)
Immuno-oncology (60)
Indications (56)
Infectious disease (391)
Inflammatory bowel disease (36)
Inflation Reduction Act (3)
Influenza (15)
Intellectual property (57)
Interviews (12)
IPO (2992)
IRA (8)
Job creations (484)
Job search strategy (70)
JPM (25)
Kidney cancer (17)
Labor market (10)
Layoffs (141)
Leadership (6)
Legal (477)
Liver cancer (48)
Longevity (1)
Lung cancer (527)
Lymphoma (226)
Machine learning (14)
Management (3)
Manufacturing (137)
MASH (7)
Medical device (879)
Medtech (884)
Mergers & acquisitions (3263)
Metabolic disorders (107)
Multiple sclerosis (15)
NASH (1)
Neurodegenerative disease (30)
Neuropsychiatric disorders (9)
Neuroscience (321)
NextGen: Class of 2026 (955)
Non-profit (503)
Now hiring (18)
Obesity (61)
Opinion (38)
Ovarian cancer (132)
Pain (27)
Pancreatic cancer (169)
Parkinson's disease (32)
Partnered (1)
Patents (94)
Patient recruitment (162)
Peanut (2)
People (13502)
Pharmaceutical (12)
Pharmacy benefit managers (3)
Phase 1 (8022)
Phase 2 (8884)
Phase 3 (6847)
Pipeline (1710)
Policy (33)
Postmarket research (472)
Preclinical (2536)
Press Release (2)
Prostate cancer (171)
Psychedelics (4)
Radiopharmaceuticals (189)
Rare diseases (146)
Real estate (752)
Recruiting (5)
Regulatory (4784)
Reports (9)
Research institute (697)
Resumes & cover letters (11)
RNA editing (2)
RSV (10)
Schizophrenia (37)
Series A (65)
Series B (30)
Service/supplier (1)
Sickle cell disease (37)
Special edition (4)
Spinal muscular atrophy (16)
Sponsored (6)
Startups (766)
State (1)
Stomach cancer (12)
Supply chain (12)
Tariffs (8)
The Weekly (18)
Vaccines (191)
Venture capital (34)
Weight loss (25)
Women's health (6)
Date
Today (44)
Last 7 days (151)
Last 30 days (585)
Last 365 days (8392)
2026 (1038)
2025 (8405)
2024 (9466)
2023 (10639)
2022 (13111)
2021 (13176)
2020 (10961)
2019 (8592)
2018 (6333)
2017 (7122)
2016 (6284)
2015 (6948)
2014 (4524)
2013 (3091)
2012 (3341)
2011 (3329)
2010 (3038)
Location
Africa (88)
Alabama (19)
Alaska (1)
Arizona (25)
Arkansas (2)
Asia (11412)
Australia (1543)
California (3159)
Canada (708)
China (599)
Colorado (83)
Connecticut (129)
Delaware (241)
Europe (20785)
Florida (419)
Georgia (12)
Idaho (6)
Illinois (309)
India (19)
Indiana (102)
Iowa (9)
Japan (209)
Kansas (10)
Kentucky (13)
Maine (4)
Maryland (337)
Massachusetts (2488)
Michigan (28)
Minnesota (111)
Missouri (12)
Montana (8)
Nebraska (2)
Nevada (10)
New Hampshire (10)
New Jersey (892)
New Mexico (3)
New York (751)
North Carolina (242)
Northern California (1675)
Ohio (66)
Oklahoma (1)
Oregon (5)
Pennsylvania (468)
Puerto Rico (3)
Rhode Island (6)
South America (117)
South Carolina (3)
Southern California (1244)
Tennessee (36)
Texas (546)
United States (10637)
Utah (75)
Virginia (27)
Washington D.C. (9)
Washington State (295)
Wisconsin (37)
131,411 Results for "ikena oncology".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals
July 16, 2025
·
8 min read
Press Releases
Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million
July 28, 2025
·
9 min read
Press Releases
Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company
July 24, 2025
·
10 min read
Genetown
Ikena Oncology Announces Strategic Update
Ikena Oncology, Inc. announced discontinuation of the clinical IK-930 program, the Company’s TEAD1- selective Hippo pathway inhibitor and continued clinical development of IK-595, a novel MEK-RAF molecular glue.
May 28, 2024
·
5 min read
Genetown
Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum
Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will present a corporate overview at the Stifel 2024 Targeted Oncology Forum, taking place virtually from April 16-17, 2024.
April 10, 2024
·
3 min read
Genetown
UPDATE – Ikena Oncology Announces Strategic Update
Ikena Oncology, Inc. announced discontinuation of the clinical IK-930 program, the Company’s TEAD1- selective Hippo pathway inhibitor and continued clinical development of IK-595, a novel MEK-RAF molecular glue.
May 28, 2024
·
5 min read
Business
Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update
Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced financial results for the first quarter ended March 31, 2024.
May 13, 2024
·
6 min read
Business
Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer
Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced the resignation of Dr. Sergio Santillana and the appointment of Dr. Caroline Germa as Chief Medical Officer.
February 21, 2024
·
6 min read
Genetown
Ikena Oncology to Participate in TD Cowen 44th Annual Health Care Conference
Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will participate in a targeted oncology panel at the TD Cowen 44th Annual Health Care Conference, taking place March 4-6, 2024, in Boston, MA.
February 27, 2024
·
4 min read
Business
Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
Ikena Oncology, Inc., a targeted oncology company forging new territory in patient-directed cancer treatment, announced financial results for the fourth quarter and full year ending December 31, 2023.
March 12, 2024
·
7 min read
1 of 13,142
Next
